Nonmelanoma Skin Cancer in Patients Older Than Age 85 Years Presenting for Mohs Surgery: A Prospective, Multicenter Cohort Study.
Journal
JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
26
5
2022
medline:
23
7
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
It has been suggested that Mohs surgery for skin cancer among individuals with limited life expectancy may be associated with needless risk and discomfort, along with increased health care costs. To investigate patient- and tumor-specific indications considered by clinicians for treatment of nonmelanoma skin cancer in older individuals. This multicenter, prospective cohort study was conducted using data from US private practice and academic centers. Included patients were those older than age 85 years presenting for skin cancer surgery and referred for Mohs surgery, with reference groups of those younger than age 85 years receiving Mohs surgery and those older than age 85 years not receiving Mohs surgery. Data were analyzed from November 2018 through January 2019. Mohs surgery for nonmelanoma skin cancer. Reason for treatment selection. Among 1181 patients older than age 85 years referred for Mohs surgery (724 [61.9%] men among 1169 patients with sex data; 681 individuals aged >85 to 88 years [57.9%] among 1176 patients with age data) treated at 22 sites, 1078 patients (91.3%) were treated by Mohs surgery, and 103 patients (8.7%) received alternate treatment. Patients receiving Mohs surgery were more likely to have tumors on the face (738 patients [68.5%] vs 26 patients [25.2%]; P < .001) and nearly 4-fold more likely to have high functional status (614 patients [57.0%] vs 16 patients [15.5%]; P < .001). Of 15 distinct reasons provided by surgeons for opting to proceed with Mohs surgery, the most common were patient desire for treatment with a high cure rate (712 patients [66.0%]), good or excellent patient functional status for age (614 patients [57.0%]), and high risk associated with the tumor based on histology (433 patients [40.2%]). This study found that older patients who received Mohs surgery often had high functional status, high-risk tumors, and tumors located on the face. These findings suggest that timely surgical treatment may be appropriate in older patients given that their tumors may be aggressive, painful, disfiguring, and anxiety provoking.
Identifiants
pubmed: 35612849
pii: 2792450
doi: 10.1001/jamadermatol.2022.1733
pmc: PMC9134038
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
770-778Références
NAM Perspect. 2020 Mar 05;2020:
pubmed: 34532682
J Am Acad Dermatol. 2002 Sep;47(3):419-22
pubmed: 12196753
Dermatol Clin. 2019 Jul;37(3):279-286
pubmed: 31084722
J Am Acad Dermatol. 2018 Jun;78(6):1119-1124
pubmed: 29288096
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):108-112
pubmed: 28898467
Vital Health Stat 2. 2012 Jan;(154):1-65
pubmed: 22783637
Dermatol Surg. 1997 May;23(5):389-92; discussion 392-3
pubmed: 9179250
Dermatol Surg. 2021 Apr 1;47(4):551-552
pubmed: 33795575
J Drugs Dermatol. 2018 May 1;17(5):499-505
pubmed: 29742179
J Am Acad Dermatol. 2018 Mar;78(3):560-578
pubmed: 29331386
BMC Med Inform Decis Mak. 2013 Jul 19;13:72
pubmed: 23870327
Dermatol Surg. 2014 Jun;40(6):686-90
pubmed: 24852474
J Am Acad Dermatol. 2013 Feb;68(2):296-300
pubmed: 23200199
Dermatol Surg. 2017 Jul;43(7):904-910
pubmed: 28328703
J Am Acad Dermatol. 2018 Mar;78(3):540-559
pubmed: 29331385
JAMA Intern Med. 2013 Jun 10;173(11):1006-12
pubmed: 23699934
Dermatol Surg. 2020 Mar;46(3):319-326
pubmed: 31356441